FibroGen CEO Conterno, who scrapped post-Lilly plans over roxadustat hype, resigns after launch setbacks
Fierce Pharma
JULY 25, 2023
Hopes around FibroGen’s anemia drug roxadustat were high in early 2020 when Enrique Conterno arrived as the company’s new CEO. To support Wettig, Conterno plans to stick around as a special advisor to the CEO during a transition period.
Let's personalize your content